Raras
Buscar doenças, sintomas, genes...
Acidúria orgânica clássica
ORPHA:79163CID-11 · 5C50.E0DOENÇA RARA

Acido metilmalônico é um composto químico do grupo dos ácidos dicarboxílicos. É constituído pela estrutura básica do ácido malónico e contém também um grupo metilo. Os sais do ácido metilmalónico são denominados metilmalonatos.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Doença metabólica rara caracterizada por hiperalaninemia e sintomas neurológicos como convulsões e lesões nos gânglios da base. Pode apresentar trombocitopenia, fraqueza muscular e distúrbios gastrointestinais.

Publicações científicas
82 artigos
Último publicado: 2025 Jul 24
Medicamentos
1 registrados
CARGLUMIC ACID

Tem tratamento?

1 medicamento registrado
Ver detalhes, fases e interações →
CARGLUMIC ACID
🏥
SUS: Cobertura mínimaScore: 25%
Triagem neonatal (Fase 2)Centros em: PA, PR, SC, RS, ES +8
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧠
Neurológico
81 sintomas
❤️
Coração
26 sintomas
👁️
Olhos
23 sintomas
🩸
Sangue
21 sintomas
🫘
Rins
21 sintomas
🫃
Digestivo
20 sintomas

+ 199 sintomas em outras categorias

Características mais comuns

Hiperalaninemia
Olho profundamente inserido
Trombocitopenia
Lesões bilaterais dos gânglios da base
Fraqueza muscular
Náusea e vômito
488sintomas
Sem dados (488)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 488 características clínicas mais associadas, ordenadas por frequência.

HiperalaninemiaHyperalaninemia
Olho profundamente inseridoDeeply set eye
TrombocitopeniaThrombocytopenia
Lesões bilaterais dos gânglios da baseBilateral basal ganglia lesions
Fraqueza muscularMuscle weakness

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa11
Total histórico82PubMed
Últimos 10 anos18publicações
Pico20254 papers
Linha do tempo
20202015Hoje · 2026📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Triagem neonatal (Teste do Pezinho)

👶
Teste: MS/MS — acilcarnitinas + ácidos orgânicos
Fase 2 do PNTNin_rollout
Incidência no Brasil: 1:20.000

A triagem neonatal permite diagnóstico precoce e início imediato do tratamento.

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

32 genes identificados com associação a esta condição.

ACAT1Sterol O-acyltransferase 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the formation of fatty acid-cholesterol esters, which are less soluble in membranes than cholesterol (PubMed:16154994, PubMed:16647063, PubMed:32433613, PubMed:32433614, PubMed:32944968, PubMed:9020103). Plays a role in lipoprotein assembly and dietary cholesterol absorption (PubMed:16154994, PubMed:9020103). Preferentially utilizes oleoyl-CoA ((9Z)-octadecenoyl-CoA) as a substrate: shows a higher activity towards an acyl-CoA substrate with a double bond at the delta-9 position (9Z) th

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (5)
Branched-chain amino acid catabolismUtilization of Ketone BodiesSynthesis of Ketone BodiesMaturation of TCA enzymes and regulation of TCA cycleMitochondrial protein degradation
VIAS REACTOME (1)
OUTRAS DOENÇAS (1)
beta-ketothiolase deficiency
HGNC:93UniProt:P35610
ABCD4Lysosomal cobalamin transporter ABCD4Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Lysosomal membrane protein that transports cobalamin (Vitamin B12) from the lysosomal lumen to the cytosol in an ATP-dependent manner (PubMed:22922874, PubMed:28572511, PubMed:31467407, PubMed:33845046). Targeted by LMBRD1 lysosomal chaperone from the endoplasmic reticulum to the lysosomal membrane (PubMed:27456980). Then forms a complex with lysosomal chaperone LMBRD1 and cytosolic MMACHC to transport cobalamin across the lysosomal membrane (PubMed:25535791)

LOCALIZAÇÃO

Endoplasmic reticulum membraneLysosome membrane

VIAS BIOLÓGICAS (2)
Transport of RCbl within the bodyUptake of dietary cobalamins into enterocytes
MECANISMO DE DOENÇA

Methylmalonic aciduria and homocystinuria type cblJ

A disorder of cobalamin metabolism characterized by decreased levels of the coenzymes adenosylcobalamin (AdoCbl) and methylcobalamin (MeCbl). Clinical features include feeding difficulties, poor growth, hypotonia, lethargy, anemia, and developmental delay.

OUTRAS DOENÇAS (1)
methylmalonic acidemia with homocystinuria, type cblJ
HGNC:68UniProt:O14678
PCCAPropionyl-CoA carboxylase alpha chain, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

This is one of the 2 subunits of the biotin-dependent propionyl-CoA carboxylase (PCC), a mitochondrial enzyme involved in the catabolism of odd chain fatty acids, branched-chain amino acids isoleucine, threonine, methionine, and valine and other metabolites (PubMed:6765947, PubMed:8434582). Propionyl-CoA carboxylase catalyzes the carboxylation of propionyl-CoA/propanoyl-CoA to D-methylmalonyl-CoA/(S)-methylmalonyl-CoA (PubMed:10101253, PubMed:6765947, PubMed:8434582). Within the holoenzyme, the

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (2)
Defective HLCS causes multiple carboxylase deficiencyBiotin transport and metabolism
MECANISMO DE DOENÇA

Propionic acidemia type I

Life-threatening disease characterized by episodic vomiting, lethargy and ketosis, neutropenia, periodic thrombocytopenia, hypogammaglobulinemia, developmental retardation, and intolerance to protein.

EXPRESSÃO TECIDUAL(Ubíquo)
Glândula adrenal
26.2 TPM
Rim - Córtex
18.4 TPM
Cérebro - Hemisfério cerebelar
16.5 TPM
Rim - Medula
16.4 TPM
Cólon transverso
14.4 TPM
OUTRAS DOENÇAS (1)
propionic acidemia
HGNC:8653UniProt:P05165
HIBCH3-hydroxyisobutyryl-CoA hydrolase, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Hydrolyzes 3-hydroxyisobutyryl-CoA (HIBYL-CoA), a saline catabolite. Has high activity toward isobutyryl-CoA. Could be an isobutyryl-CoA dehydrogenase that functions in valine catabolism. Also hydrolyzes 3-hydroxypropanoyl-CoA

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (1)
Branched-chain amino acid catabolism
MECANISMO DE DOENÇA

3-hydroxyisobutryl-CoA hydrolase deficiency

An autosomal recessive inborn error of valine metabolism. It causes severely delayed psychomotor development, neurodegeneration, increased lactic acid, and brain lesions in the basal ganglia.

EXPRESSÃO TECIDUAL(Ubíquo)
Glândula adrenal
39.4 TPM
Cervix Ectocervix
27.1 TPM
Aorta
27.0 TPM
Cervix Endocervix
22.7 TPM
Fígado
22.6 TPM
OUTRAS DOENÇAS (1)
3-hydroxyisobutyryl-CoA hydrolase deficiency
HGNC:4908UniProt:Q6NVY1
BTDBiotinidaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalytic release of biotin from biocytin, the product of biotin-dependent carboxylases degradation

LOCALIZAÇÃO

Secreted, extracellular space

VIAS BIOLÓGICAS (1)
Biotin transport and metabolism
MECANISMO DE DOENÇA

Biotinidase deficiency

A juvenile form of multiple carboxylase deficiency, an autosomal recessive disorder of biotin metabolism, characterized by ketoacidosis, hyperammonemia, excretion of abnormal organic acid metabolites, and dermatitis. Biotinidase deficiency is characterized by seizures, hypotonia, skin rash, alopecia, ataxia, hearing loss, and optic atrophy. If untreated, symptoms usually become progressively worse, and coma and death may occur.

OUTRAS DOENÇAS (1)
biotinidase deficiency
HGNC:1122UniProt:P43251
MMADHCCobalamin trafficking protein CblDDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Involved in cobalamin metabolism and trafficking (PubMed:18385497, PubMed:23415655, PubMed:24722857, PubMed:26364851). Plays a role in regulating the biosynthesis and the proportion of two coenzymes, methylcob(III)alamin (MeCbl) and 5'-deoxyadenosylcobalamin (AdoCbl) (PubMed:18385497, PubMed:23415655, PubMed:24722857). Promotes oxidation of cob(II)alamin bound to MMACHC (PubMed:26364851). The processing of cobalamin in the cytosol occurs in a multiprotein complex composed of at least MMACHC, MMA

LOCALIZAÇÃO

CytoplasmMitochondrion

VIAS BIOLÓGICAS (1)
Cobalamin (Cbl) metabolism
MECANISMO DE DOENÇA

Methylmalonic aciduria and homocystinuria, cblD type

An autosomal recessive disorder of cobalamin metabolism characterized by decreased levels of the coenzymes adenosylcobalamin (AdoCbl) and methylcobalamin (MeCbl). Clinical features include developmental delay, hyotonia, intellectual disability, seizures, and megaloblastic anemia. Laboratory studies show methylmalonic aciduria and homocystinuria.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
157.4 TPM
Fibroblastos
145.1 TPM
Artéria tibial
139.0 TPM
Músculo esquelético
127.1 TPM
Aorta
115.0 TPM
OUTRAS DOENÇAS (5)
methylmalonic aciduria and homocystinuria type cblDhomocystinuria-megaloblastic anemia cblD typeisolated methylmalonic aciduria cblD typemethylcobalamin deficiency type cblDv1
HGNC:25221UniProt:Q9H3L0
ACADSBShort/branched chain specific acyl-CoA dehydrogenase, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Short and branched chain specific acyl-CoA dehydrogenase that catalyzes the proR-proR stereospecific alpha,beta-dehydrogenation of fatty acyl-CoA thioesters using the electron transfer flavoprotein (ETF) as their physiologic electron acceptor, resulting in the formation of trans-2-enoyl-CoA ((2E)-enoyl-CoA) (PubMed:10832746, PubMed:11013134, PubMed:21430231, PubMed:7698750). Among the different mitochondrial acyl-CoA dehydrogenases, acts specifically on short and branched chain acyl-CoA derivati

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (2)
Branched-chain amino acid catabolismMitochondrial protein degradation
MECANISMO DE DOENÇA

Short/branched-chain acyl-CoA dehydrogenase deficiency

Autosomal recessive disorder and consists of a defect in catabolism of L-isoleucine which is characterized by an increase of 2-methylbutyrylglycine and 2-methylbutyrylcarnitine in blood and urine. Affected individuals have seizures and psychomotor delay as the main clinical features.

OUTRAS DOENÇAS (1)
2-methylbutyryl-CoA dehydrogenase deficiency
HGNC:91UniProt:P45954
PCCBPropionyl-CoA carboxylase beta chain, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

This is one of the 2 subunits of the biotin-dependent propionyl-CoA carboxylase (PCC), a mitochondrial enzyme involved in the catabolism of odd chain fatty acids, branched-chain amino acids isoleucine, threonine, methionine, and valine and other metabolites (PubMed:15890657, PubMed:6765947). Propionyl-CoA carboxylase catalyzes the carboxylation of propionyl-CoA/propanoyl-CoA to D-methylmalonyl-CoA/(S)-methylmalonyl-CoA (PubMed:15890657, PubMed:6765947). Within the holoenzyme, the alpha subunit c

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (3)
Propionyl-CoA catabolismBiotin transport and metabolismMitochondrial protein degradation
MECANISMO DE DOENÇA

Propionic acidemia type II

Life-threatening disease characterized by episodic vomiting, lethargy and ketosis, neutropenia, periodic thrombocytopenia, hypogammaglobulinemia, developmental retardation, and intolerance to protein.

EXPRESSÃO TECIDUAL(Ubíquo)
Glândula adrenal
39.5 TPM
Linfócitos
31.7 TPM
Testículo
27.0 TPM
Fígado
21.1 TPM
Fibroblastos
15.0 TPM
OUTRAS DOENÇAS (1)
propionic acidemia
HGNC:8654UniProt:P05166
TIMM50Mitochondrial import inner membrane translocase subunit TIM50Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Essential component of the TIM23 complex, a complex that mediates the translocation of transit peptide-containing proteins across the mitochondrial inner membrane (PubMed:30190335, PubMed:38828998). Has some phosphatase activity in vitro; however such activity may not be relevant in vivo May participate in the release of snRNPs and SMN from the Cajal body

LOCALIZAÇÃO

Mitochondrion inner membraneNucleus speckle

VIAS BIOLÓGICAS (1)
Mitochondrial protein import
MECANISMO DE DOENÇA

3-methylglutaconic aciduria 9

An autosomal recessive disease characterized by early-onset seizures, severely delayed psychomotor development and intellectual disability. Patients have hypotonia or spasticity, and laboratory investigations show increased serum lactate and 3-methylglutaconic aciduria.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
66.7 TPM
Fibroblastos
38.0 TPM
Linfócitos
34.0 TPM
Tireoide
31.4 TPM
Útero
29.1 TPM
OUTRAS DOENÇAS (1)
3-methylglutaconic aciduria type 9
HGNC:23656UniProt:Q3ZCQ8
TAFAZZINTafazzinDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Acyltransferase required to remodel newly synthesized phospholipid cardiolipin (1',3'-bis-[1,2-diacyl-sn-glycero-3-phospho]-glycerol or CL), a key component of the mitochondrial inner membrane, with tissue specific acyl chains necessary for adequate mitochondrial function (PubMed:12930833, PubMed:19164547, PubMed:19700766, PubMed:26908608, PubMed:33096711). Its role in cellular physiology is to improve mitochondrial performance (PubMed:32234310). CL is critical for the coassembly of lipids and p

LOCALIZAÇÃO

Mitochondrion outer membraneMitochondrion inner membraneMitochondrion membraneCytoplasm

VIAS BIOLÓGICAS (2)
Acyl chain remodeling of CLMitochondrial protein import
MECANISMO DE DOENÇA

Barth syndrome

An X-linked disease characterized by dilated cardiomyopathy with endocardial fibroelastosis, a predominantly proximal skeletal myopathy, growth retardation, neutropenia, and organic aciduria, particularly excess of 3-methylglutaconic acid. Additional features include hypertrophic cardiomyopathy, isolated left ventricular non-compaction, ventricular arrhythmia, motor delay, poor appetite, fatigue and exercise intolerance, hypoglycemia, lactic acidosis, hyperammonemia, and dramatic late catch-up growth after growth delay throughout childhood.

OUTRAS DOENÇAS (2)
Barth syndromefamilial isolated dilated cardiomyopathy
HGNC:11577UniProt:Q16635
HLCSBiotin--protein ligaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Biotin--protein ligase catalyzing the biotinylation of the 4 biotin-dependent carboxylases acetyl-CoA-carboxylase, pyruvate carboxylase, propionyl-CoA carboxylase, and methylcrotonyl-CoA carboxylase

LOCALIZAÇÃO

CytoplasmMitochondrion

VIAS BIOLÓGICAS (1)
Biotin transport and metabolism
MECANISMO DE DOENÇA

Holocarboxylase synthetase deficiency

A neonatal form of multiple carboxylase deficiency, an autosomal recessive disorder of biotin metabolism, characterized by ketoacidosis, hyperammonemia, excretion of abnormal organic acid metabolites, and dermatitis. In holocarboxylase synthetase deficiency, clinical and biochemical symptoms improve dramatically with administration of biotin.

EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
14.6 TPM
Fibroblastos
12.2 TPM
Próstata
9.8 TPM
Tireoide
9.7 TPM
Cérebro - Hemisfério cerebelar
9.3 TPM
OUTRAS DOENÇAS (1)
holocarboxylase synthetase deficiency
HGNC:4976UniProt:P50747
MMABCorrinoid adenosyltransferase MMABDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Converts cob(I)alamin to adenosylcobalamin (adenosylcob(III)alamin), a coenzyme for methylmalonyl-CoA mutase, therefore participates in the final step of the vitamin B12 conversion (PubMed:12514191). Generates adenosylcobalamin (AdoCbl) and directly delivers the cofactor to MUT in a transfer that is stimulated by ATP-binding to MMAB and gated by MMAA (Probable)

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (1)
Cobalamin (Cbl) metabolism
MECANISMO DE DOENÇA

Methylmalonic aciduria, cblB type

An autosomal recessive disorder of methylmalonate and cobalamin metabolism due to defective synthesis of adenosylcobalamin.

EXPRESSÃO TECIDUAL(Ubíquo)
Glândula adrenal
23.8 TPM
Fígado
21.8 TPM
Tireoide
18.6 TPM
Rim - Medula
18.1 TPM
Ovário
16.9 TPM
OUTRAS DOENÇAS (1)
methylmalonic aciduria, cblB type
HGNC:19331UniProt:Q96EY8
CLPBMitochondrial disaggregaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Functions as a regulatory ATPase and participates in secretion/protein trafficking process. Has ATP-dependent protein disaggregase activity and is required to maintain the solubility of key mitochondrial proteins (PubMed:32573439, PubMed:34115842, PubMed:35247700, PubMed:36170828, PubMed:36745679). Involved in mitochondrial-mediated antiviral innate immunity, activates RIG-I-mediated signal transduction and production of IFNB1 and pro-inflammatory cytokine IL6 (PubMed:31522117). Plays a role in

LOCALIZAÇÃO

Mitochondrion intermembrane space

MECANISMO DE DOENÇA

3-methylglutaconic aciduria 7B

An autosomal recessive inborn error of metabolism with a highly variable phenotype. Primary disease symptoms are increased levels of 3-methylglutaconic acid, neurologic deterioration and neutropenia. Other common features include progressive encephalopathy, movement abnormalities, delayed psychomotor development,impaired intellectual development, cataracts, seizures, and recurrent infections.

OUTRAS DOENÇAS (4)
neutropenia, severe congenital, 9, autosomal dominant3-methylglutaconic aciduria, type VIIA3-methylglutaconic aciduria, type VIIBautosomal dominant severe congenital neutropenia
HGNC:30664UniProt:Q9H078
LMBRD1Lysosomal cobalamin transport escort protein LMBD1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Lysosomal membrane chaperone required to export cobalamin (vitamin B12) from the lysosome to the cytosol, allowing its conversion to cofactors (PubMed:19136951). Targets ABCD4 transporter from the endoplasmic reticulum to the lysosome (PubMed:27456980). Then forms a complex with lysosomal ABCD4 and cytoplasmic MMACHC to transport cobalamin across the lysosomal membrane (PubMed:25535791). Acts as an adapter protein which plays an important role in mediating and regulating the internalization of t

LOCALIZAÇÃO

Endoplasmic reticulum membraneLysosome membraneCell membraneCytoplasmic vesicle, clathrin-coated vesicle

VIAS BIOLÓGICAS (3)
Transport of RCbl within the bodyUptake of dietary cobalamins into enterocytesDefective ABCD4 causes MAHCJ
MECANISMO DE DOENÇA

Methylmalonic aciduria and homocystinuria, cblF type

An autosomal recessive disorder of cobalamin metabolism characterized by decreased levels of the coenzymes adenosylcobalamin (AdoCbl) and methylcobalamin (MeCbl). It is due to accumulation of free cobalamin in lysosomes, thus hindering its conversion to cofactors. Clinical features include developmental delay, stomatitis, glossitis, seizures and methylmalonic aciduria responsive to vitamin B12.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Spinal cord cervical c-1
108.4 TPM
Nervo tibial
106.7 TPM
Cérebro - Hemisfério cerebelar
91.9 TPM
Tireoide
82.0 TPM
Glândula adrenal
77.1 TPM
OUTRAS DOENÇAS (1)
methylmalonic aciduria and homocystinuria type cblF
HGNC:23038UniProt:Q9NUN5
HCFC1Host cell factor 1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Transcriptional coregulator (By similarity). Serves as a scaffold protein, bridging interactions between transcription factors, including THAP11 and ZNF143, and transcriptional coregulators (PubMed:26416877). Involved in control of the cell cycle (PubMed:10629049, PubMed:10779346, PubMed:15190068, PubMed:16624878, PubMed:23629655). Also antagonizes transactivation by ZBTB17 and GABP2; represses ZBTB17 activation of the p15(INK4b) promoter and inhibits its ability to recruit p300 (PubMed:10675337

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (4)
HATs acetylate histonesFormation of WDR5-containing histone-modifying complexesTranscriptional activation of mitochondrial biogenesisUCH proteinases
MECANISMO DE DOENÇA

Methylmalonic aciduria and homocystinuria, cblX type

An X-linked recessive metabolic disorder characterized by severely delayed psychomotor development apparent in infancy, failure to thrive, impaired intellectual development, and intractable epilepsy. Additional features may include microcephaly and choreoathetosis.

EXPRESSÃO TECIDUAL(Ubíquo)
Útero
47.3 TPM
Linfócitos
43.8 TPM
Cerebelo
38.2 TPM
Fallopian Tube
37.2 TPM
Ovário
35.7 TPM
OUTRAS DOENÇAS (2)
methylmalonic acidemia with homocystinuria, type cblXnon-syndromic X-linked intellectual disability
HGNC:4839UniProt:P51610
MMACHCCyanocobalamin reductase / alkylcobalamin dealkylaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Cobalamin (vitamin B12) cytosolic chaperone that catalyzes the reductive decyanation of cyanocob(III)alamin (cyanocobalamin, CNCbl) to yield cob(II)alamin and cyanide, using FAD or FMN as cofactors and NADPH as cosubstrate (PubMed:18779575, PubMed:19700356, PubMed:21697092, PubMed:25809485). Cyanocobalamin constitutes the inactive form of vitamin B12 introduced from the diet, and is converted into the active cofactors methylcobalamin (MeCbl) involved in methionine biosynthesis, and 5'-deoxyadeno

LOCALIZAÇÃO

Cytoplasm, cytosol

VIAS BIOLÓGICAS (2)
Cobalamin (Cbl) metabolismDefective MMADHC causes MMAHCD
MECANISMO DE DOENÇA

Methylmalonic aciduria and homocystinuria, cblC type

An autosomal recessive disorder of cobalamin metabolism characterized by decreased levels of the coenzymes adenosylcobalamin (AdoCbl) and methylcobalamin (MeCbl). Affected individuals may have developmental, hematologic, neurologic, metabolic, ophthalmologic, and dermatologic clinical findings. Although considered a disease of infancy or childhood, some individuals develop symptoms in adulthood.

EXPRESSÃO TECIDUAL(Ubíquo)
Fígado
9.1 TPM
Testículo
7.5 TPM
Fibroblastos
6.7 TPM
Linfócitos
5.8 TPM
Glândula adrenal
4.4 TPM
OUTRAS DOENÇAS (1)
methylmalonic aciduria and homocystinuria type cblC
HGNC:24525UniProt:Q9Y4U1
PRDX1Peroxiredoxin-1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Thiol-specific peroxidase that catalyzes the reduction of hydrogen peroxide and organic hydroperoxides to water and alcohols, respectively. Plays a role in cell protection against oxidative stress by detoxifying peroxides and as sensor of hydrogen peroxide-mediated signaling events. Might participate in the signaling cascades of growth factors and tumor necrosis factor-alpha by regulating the intracellular concentrations of H(2)O(2) (PubMed:9497357). Reduces an intramolecular disulfide bond in G

LOCALIZAÇÃO

CytoplasmMelanosome

VIAS BIOLÓGICAS (4)
TP53 Regulates Metabolic GenesNFE2L2 regulating anti-oxidant/detoxification enzymesDetoxification of Reactive Oxygen SpeciesDeregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
EXPRESSÃO TECIDUAL(Ubíquo)
Esôfago - Mucosa
790.6 TPM
Tireoide
635.9 TPM
Linfócitos
598.5 TPM
Fibroblastos
487.5 TPM
Brain Spinal cord cervical c-1
472.8 TPM
OUTRAS DOENÇAS (1)
methylmalonic aciduria and homocystinuria type cblC
HGNC:HGNC:9352UniProt:Q06830
MMUTMethylmalonyl-CoA mutase, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the reversible isomerization of methylmalonyl-CoA (MMCoA) (generated from branched-chain amino acid metabolism and degradation of dietary odd chain fatty acids and cholesterol) to succinyl-CoA (3-carboxypropionyl-CoA), a key intermediate of the tricarboxylic acid cycle

LOCALIZAÇÃO

Mitochondrion matrixMitochondrionCytoplasm

VIAS BIOLÓGICAS (3)
Cobalamin (Cbl) metabolismPropionyl-CoA catabolismDefective MMAA causes MMA, cblA type
MECANISMO DE DOENÇA

Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency

An often fatal disorder of organic acid metabolism. Common clinical features include lethargy, vomiting, failure to thrive, hypotonia, neurological deficit and early death. Two forms of the disease are distinguished by the presence (mut-) or absence (mut0) of residual enzyme activity. Mut0 patients have more severe neurological manifestations of the disease than do MUT- patients. MAMM is unresponsive to vitamin B12 therapy.

OUTRAS DOENÇAS (3)
methylmalonic aciduria due to methylmalonyl-CoA mutase deficiencyvitamin B12-unresponsive methylmalonic acidemia type mut-vitamin B12-unresponsive methylmalonic acidemia type mut0
HGNC:7526UniProt:P22033
HMGCLHydroxymethylglutaryl-CoA lyase, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Mitochondrial 3-hydroxy-3-methylglutaryl-CoA lyase that catalyzes a cation-dependent cleavage of (S)-3-hydroxy-3-methylglutaryl-CoA into acetyl-CoA and acetoacetate, a key step in ketogenesis. Terminal step in leucine catabolism. Ketone bodies (beta-hydroxybutyrate, acetoacetate and acetone) are essential as an alternative source of energy to glucose, as lipid precursors and as regulators of metabolism

LOCALIZAÇÃO

Mitochondrion matrixPeroxisome

VIAS BIOLÓGICAS (1)
Synthesis of Ketone Bodies
MECANISMO DE DOENÇA

3-hydroxy-3-methylglutaryl-CoA lyase deficiency

An autosomal recessive disease affecting ketogenesis and L-leucine catabolism. The disease usually appears in the first year of life after a fasting period and its clinical acute symptoms include vomiting, seizures, metabolic acidosis, hypoketotic hypoglycemia and lethargy. These symptoms sometimes progress to coma, with fatal outcome in some cases.

EXPRESSÃO TECIDUAL(Ubíquo)
Fígado
77.6 TPM
Glândula adrenal
34.4 TPM
Rim - Medula
31.9 TPM
Tireoide
29.5 TPM
Rim - Córtex
28.9 TPM
OUTRAS DOENÇAS (1)
3-hydroxy-3-methylglutaric aciduria
HGNC:5005UniProt:P35914
MCCC2Methylcrotonoyl-CoA carboxylase beta chain, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Carboxyltransferase subunit of the 3-methylcrotonyl-CoA carboxylase, an enzyme that catalyzes the conversion of 3-methylcrotonyl-CoA to 3-methylglutaconyl-CoA, a critical step for leucine and isovaleric acid catabolism

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (3)
Branched-chain amino acid catabolismBiotin transport and metabolism3-Methylcrotonyl-CoA carboxylase deficiency
MECANISMO DE DOENÇA

3-methylcrotonoyl-CoA carboxylase 2 deficiency

An autosomal recessive disorder of leucine catabolism. The phenotype is variable, ranging from neonatal onset with severe neurological involvement to asymptomatic adults. There is a characteristic organic aciduria with massive excretion of 3-hydroxyisovaleric acid and 3-methylcrotonylglycine, usually in combination with a severe secondary carnitine deficiency.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
63.1 TPM
Glândula adrenal
47.8 TPM
Tireoide
39.6 TPM
Próstata
37.3 TPM
Fígado
35.7 TPM
OUTRAS DOENÇAS (2)
3-methylcrotonyl-CoA carboxylase 2 deficiency3-methylcrotonyl-CoA carboxylase deficiency
HGNC:6937UniProt:Q9HCC0
MCCC1Methylcrotonoyl-CoA carboxylase subunit alpha, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Biotin-attachment subunit of the 3-methylcrotonyl-CoA carboxylase, an enzyme that catalyzes the conversion of 3-methylcrotonyl-CoA to 3-methylglutaconyl-CoA, a critical step for leucine and isovaleric acid catabolism

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (2)
Defective HLCS causes multiple carboxylase deficiencyBiotin transport and metabolism
MECANISMO DE DOENÇA

3-methylcrotonoyl-CoA carboxylase 1 deficiency

An autosomal recessive disorder of leucine catabolism. The phenotype is variable, ranging from neonatal onset with severe neurological involvement to asymptomatic adults. There is a characteristic organic aciduria with massive excretion of 3-hydroxyisovaleric acid and 3-methylcrotonylglycine, usually in combination with a severe secondary carnitine deficiency.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
35.9 TPM
Ovário
28.1 TPM
Glândula adrenal
26.9 TPM
Tireoide
25.8 TPM
Nervo tibial
25.6 TPM
OUTRAS DOENÇAS (2)
3-methylcrotonyl-CoA carboxylase 1 deficiency3-methylcrotonyl-CoA carboxylase deficiency
HGNC:6936UniProt:Q96RQ3
HTRA2Serine protease HTRA2, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Serine protease that shows proteolytic activity against a non-specific substrate beta-casein (PubMed:10873535). Promotes apoptosis by either relieving the inhibition of BIRC proteins on caspases, leading to an increase in caspase activity; or by a BIRC inhibition-independent, caspase-independent and serine protease activity-dependent mechanism (PubMed:15200957). Cleaves BIRC6 and relieves its inhibition on CASP3, CASP7 and CASP9, but it is also prone to inhibition by BIRC6 (PubMed:36758104, PubM

LOCALIZAÇÃO

Mitochondrion intermembrane spaceMitochondrion membraneEndoplasmic reticulum

VIAS BIOLÓGICAS (2)
Mitochondrial unfolded protein response (UPRmt)Mitochondrial protein degradation
MECANISMO DE DOENÇA

3-methylglutaconic aciduria 8

An autosomal recessive inborn error of metabolism resulting in early death. Clinical features include extreme hypertonia observed at birth, alternating with hypotonia, subsequent appearance of extrapyramidal symptoms, lack of psychomotor development, microcephaly, and intractable seizures. Patients show lactic acidemia, 3-methylglutaconic aciduria, intermittent neutropenia, and progressive brain atrophy.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
62.3 TPM
Útero
44.3 TPM
Cervix Ectocervix
44.1 TPM
Ovário
44.0 TPM
Cervix Endocervix
43.3 TPM
OUTRAS DOENÇAS (3)
3-methylglutaconic aciduria type 8young-onset Parkinson diseaseParkinson disease 13, autosomal dominant, susceptibility to
HGNC:14348UniProt:O43464
SERAC1Protein SERAC1Disease-causing germline mutation(s) inRestrito
FUNÇÃO

Facilitates the transport of serine from the cytosol to the mitochondria by interacting with and stabilizing Sideroflexin-1 (SFXN1), a mitochondrial serine transporter, playing a fundamental role in the one-carbon cycle responsible for the synthesis of nucleotides needed for mitochondrial DNA replication (PubMed:35235340). Plays an important role in the phosphatidylglycerol (PG) remodeling that is essential for both mitochondrial function and intracellular cholesterol trafficking (PubMed:2268371

LOCALIZAÇÃO

Mitochondrion membraneEndoplasmic reticulumMitochondrion

MECANISMO DE DOENÇA

3-methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like syndrome

An autosomal recessive disorder characterized by childhood onset of delayed psychomotor development or psychomotor regression, sensorineural deafness, spasticity or dystonia, and increased excretion of 3-methylglutaconic acid. Brain imaging shows cerebral and cerebellar atrophy as well as lesions in the basal ganglia reminiscent of Leigh syndrome. Laboratory studies show increased serum lactate and alanine, mitochondrial oxidative phosphorylation defects, abnormal mitochondria, abnormal phosphatidylglycerol and cardiolipin profiles in fibroblasts, and abnormal accumulation of unesterified cholesterol within cells.

EXPRESSÃO TECIDUAL(Ubíquo)
Artéria tibial
7.8 TPM
Testículo
7.7 TPM
Aorta
7.2 TPM
Esôfago - Muscular
6.0 TPM
Glândula adrenal
5.7 TPM
OUTRAS DOENÇAS (1)
3-methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like syndrome
HGNC:21061UniProt:Q96JX3
OPA3Optic atrophy 3 proteinDisease-causing germline mutation(s) inTolerante
FUNÇÃO

May play some role in mitochondrial processes

LOCALIZAÇÃO

Mitochondrion

MECANISMO DE DOENÇA

3-methylglutaconic aciduria 3

An autosomal recessive metabolic disorder that causes a neuro-ophthalmologic syndrome consisting of early-onset bilateral optic atrophy, spasticity, extrapyramidal dysfunction and cognitive deficit. Urinary excretion of 3-methylglutaconic acid and 3-methylglutaric acid is increased. MGCA3 can be distinguished from MGCA1 by the absence of increase of 3-hydroxyisovaleric acid levels.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
11.2 TPM
Pituitária
8.7 TPM
Fibroblastos
7.7 TPM
Glândula adrenal
7.7 TPM
Baço
7.2 TPM
OUTRAS DOENÇAS (2)
optic atrophy 33-methylglutaconic aciduria type 3
HGNC:8142UniProt:Q9H6K4
THAP11THAP domain-containing protein 11Disease-causing germline mutation(s) inRestrito
FUNÇÃO

Transcription factor, which has both transcriptional activation and repression activities (PubMed:31905202). Also modulates chromatin accessibility (PubMed:38361031). In complex with HCFC1 and ZNF143, regulates the expression of several genes, including AP2S1, ESCO2, OPHN1, RBL1, UBXN8 and ZNF32 (PubMed:26416877). May regulate the expression of genes that encode both cytoplasmic and mitochondrial ribosomal proteins (By similarity). Required for normal mitochondrial development and function. Regu

LOCALIZAÇÃO

NucleusCytoplasm

MECANISMO DE DOENÇA

Methylmalonic aciduria and homocystinuria type cblL

An autosomal recessive disorder of cobalamin metabolism clinically characterized by early-onset seizures, and profound global developmental delay with severe intellectual disability. Metabolic features are mild methylmalonic aciduria, low-normal plasma methionine, and high-normal plasma homocysteine.

EXPRESSÃO TECIDUAL(Ubíquo)
Útero
52.0 TPM
Cervix Endocervix
50.5 TPM
Cervix Ectocervix
50.0 TPM
Cólon sigmoide
47.7 TPM
Esôfago - Junção
45.0 TPM
OUTRAS DOENÇAS (2)
spinocerebellar ataxia 51methylmalonic aciduria and homocystinuria, cb1L type
HGNC:HGNC:23194UniProt:Q96EK4
MICOS13MICOS complex subunit MIC13Candidate gene tested inTolerante
FUNÇÃO

Component of the MICOS complex, a large protein complex of the mitochondrial inner membrane that plays crucial roles in the maintenance of crista junctions, inner membrane architecture, and formation of contact sites to the outer membrane (PubMed:25997101, PubMed:27623147, PubMed:32567732). Constituent of mature MICOS complex, it is required for the formation of cristae junction (CJ) and maintenance of cristae morphology (PubMed:25997101, PubMed:27623147, PubMed:32567732). Required for the incor

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (1)
Cristae formation
MECANISMO DE DOENÇA

Combined oxidative phosphorylation deficiency 37

An autosomal recessive disorder due to mitochondrial dysfunction and characterized by hypotonia, failure to thrive, progressive neurodegeneration with neurologic deterioration after the first months of life, global developmental delay, as well as liver dysfunction. Some patients may have hypertrophic cardiomyopathy, loss of vision and hearing, and/or seizures. Death in first months or years of life is observed in most patients.

VIAS REACTOME (1)
OUTRAS DOENÇAS (2)
combined oxidative phosphorylation deficiency 373-methylglutaconic aciduria type 3
HGNC:33702UniProt:Q5XKP0
AUHMethylglutaconyl-CoA hydratase, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the fifth step in the leucine degradation pathway, the reversible hydration of 3-methylglutaconyl-CoA (3-MG-CoA) to 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) (PubMed:11738050, PubMed:12434311, PubMed:12655555, PubMed:16640564). Can catalyze the reverse reaction but at a much lower rate in vitro (PubMed:16640564). HMG-CoA is then quickly degraded by another enzyme (such as HMG-CoA lyase) to give acetyl-CoA and acetoacetate (PubMed:16640564). Uses other substrates such as (2E)-glutaconyl-

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (1)
Branched-chain amino acid catabolism
MECANISMO DE DOENÇA

3-methylglutaconic aciduria 1

An inborn error of leucine metabolism. It leads to an autosomal recessive syndrome with variable clinical phenotype, ranging from delayed speech development to severe psychomotor retardation, coma, failure to thrive, metabolic acidosis and dystonia. MGCA1 can be distinguished from other forms of MGCA by the pattern of metabolite excretion: 3-methylglutaconic acid levels are higher than those detected in other forms, whereas methylglutaric acid levels are usually only slightly elevated and there is a high level of 3-hydroxyisovaleric acid excretion (not present in other MGCA forms).

OUTRAS DOENÇAS (1)
3-methylglutaconic aciduria type 1
HGNC:890UniProt:Q13825
ACAD8Isobutyryl-CoA dehydrogenase, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Isobutyryl-CoA dehydrogenase which catalyzes the conversion of 2-methylpropanoyl-CoA to (2E)-2-methylpropenoyl-CoA in the valine catabolic pathway (PubMed:11013134, PubMed:12359132, PubMed:16857760). To a lesser extent, also able to catalyze the oxidation of (2S)-2-methylbutanoyl-CoA (PubMed:11013134, PubMed:12359132)

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (2)
Branched-chain amino acid catabolismMitochondrial protein degradation
MECANISMO DE DOENÇA

Isobutyryl-CoA dehydrogenase deficiency

An autosomal recessive metabolic disorder characterized by plasma carnitine deficiency and elevated C4-acylcarnitine. Patients manifest variable clinical features including failure to thrive, seizures, anemia, muscular hypotonia and developmental delay. Some patients may be asymptomatic.

OUTRAS DOENÇAS (1)
isobutyryl-CoA dehydrogenase deficiency
HGNC:87UniProt:Q9UKU7
DNAJC19Mitochondrial import inner membrane translocase subunit TIM14Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Mitochondrial co-chaperone which forms a complex with prohibitins to regulate cardiolipin remodeling (By similarity). May be a component of the PAM complex, a complex required for the translocation of transit peptide-containing proteins from the inner membrane into the mitochondrial matrix in an ATP-dependent manner. May act as a co-chaperone that stimulate the ATP-dependent activity (By similarity)

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (1)
Mitochondrial protein import
MECANISMO DE DOENÇA

3-methylglutaconic aciduria 5

An autosomal recessive disorder characterized by early-onset dilated cardiomyopathy, growth failure, cerebellar ataxia causing significant motor delays, testicular dysgenesis, growth failure and significant increases in urine organic acids, particularly 3-methylglutaconic acid and 3-methylglutaric acid.

EXPRESSÃO TECIDUAL(Ubíquo)
Artéria tibial
46.4 TPM
Glândula adrenal
46.0 TPM
Rim - Medula
45.7 TPM
Ovário
42.0 TPM
Pituitária
41.6 TPM
OUTRAS DOENÇAS (1)
3-methylglutaconic aciduria type 5
HGNC:30528UniProt:Q96DA6
MMAAPutative L-type amino acid transporter 1-like protein IMAADisease-causing germline mutation(s) inTolerante
LOCALIZAÇÃO

Membrane

VIAS BIOLÓGICAS (3)
Cobalamin (Cbl) metabolismPropionyl-CoA catabolismDefective MUT causes MMAM
EXPRESSÃO TECIDUAL(Ubíquo)
Fígado
5.2 TPM
Linfócitos
4.6 TPM
Testículo
3.8 TPM
Fibroblastos
3.6 TPM
Cérebro - Hemisfério cerebelar
3.5 TPM
OUTRAS DOENÇAS (1)
methylmalonic aciduria, cblA type
HGNC:18871UniProt:Q9GIP4
IVDIsovaleryl-CoA dehydrogenase, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

A mitochondrial matrix enzyme that catalyzes the third step in leucine catabolism, where isovaleryl-CoA (3-methylbutanoyl-CoA) is metabolized to 3-methylbut-2-enoyl-CoA (PubMed:7640268). To a lesser extent, it also participates in the first step in fatty acid beta-oxidation, in which it catalyzes the proR-proR stereospecific alpha,beta-dehydrogenation of other saturated short-chain acyl-CoA thioesters such as pentanoyl-CoA, hexanoyl-CoA and butanoyl-CoA, using the electron transfer flavoprotein

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (1)
Branched-chain amino acid catabolism
MECANISMO DE DOENÇA

Isovaleric acidemia

A metabolic disorder characterized by retarded psychomotor development, a peculiar odor resembling sweaty feet, an aversion to dietary protein, and pernicious vomiting, leading to acidosis and coma. The acute neonatal form leads to massive metabolic acidosis from the first days of life and rapid death.

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
164.8 TPM
Pituitária
77.9 TPM
Glândula adrenal
77.0 TPM
Fígado
66.2 TPM
Próstata
52.8 TPM
OUTRAS DOENÇAS (1)
isovaleric acidemia
HGNC:6186UniProt:P26440
ACSF3Malonate--CoA ligase ACSF3, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the initial reaction in intramitochondrial fatty acid synthesis, by activating malonate and methylmalonate, but not acetate, into their respective CoA thioester (PubMed:21841779, PubMed:21846720). May have some preference toward very-long-chain substrates (PubMed:17762044)

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (1)
Synthesis of very long-chain fatty acyl-CoAs
MECANISMO DE DOENÇA

Combined malonic and methylmalonic aciduria

A metabolic disease characterized by malonic and methylmalonic aciduria, with urinary excretion of much larger amounts of methylmalonic acid than malonic acid, in the presence of normal malonyl-CoA decarboxylase activity. Clinical features include coma, ketoacidosis, hypoglycemia, failure to thrive, microcephaly, dystonia, axial hypotonia and/or developmental delay, and neurologic manifestations including seizures, psychiatric disease and/or cognitive decline.

OUTRAS DOENÇAS (1)
combined malonic and methylmalonic acidemia
HGNC:27288UniProt:Q4G176

Medicamentos e terapias

CARGLUMIC ACIDPhase 3

Mecanismo: Carbamoyl-phosphate synthase [ammonia], mitochondrial positive allosteric modulator

Ver mais no OpenTargets

Variantes genéticas (ClinVar)

876 variantes patogênicas registradas no ClinVar.

🧬 ACAT1: NM_000019.4(ACAT1):c.677G>A (p.Trp226Ter) ()
🧬 ACAT1: NM_000019.4(ACAT1):c.339dup (p.Pro114fs) ()
🧬 ACAT1: NM_000019.4(ACAT1):c.1255G>A (p.Ala419Thr) ()
🧬 ACAT1: GRCh37/hg19 11q22.1-22.3(chr11:101504957-108516865)x1 ()
🧬 ACAT1: NM_000019.4(ACAT1):c.841G>A (p.Ala281Thr) ()
Ver todas no ClinVar

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
3Fase 31
Medicamentos catalogadosEnsaios clínicos· 1 medicamento · 0 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Acidúria orgânica clássica

Centros de Referência SUS

21 centros habilitados pelo SUS para Acidúria orgânica clássica

Centros para Acidúria orgânica clássica

Detalhes dos centros

Hospital Universitário Prof. Edgard Santos (HUPES)

R. Dr. Augusto Viana, s/n - Canela, Salvador - BA, 40110-060 · CNES 0003808

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital de Apoio de Brasília (HAB)

AENW 3 Lote A Setor Noroeste - Plano Piloto, Brasília - DF, 70684-831 · CNES 0010456

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Estadual Infantil e Maternidade Alzir Bernardino Alves (HIABA)

Av. Min. Salgado Filho, 918 - Soteco, Vila Velha - ES, 29106-010 · CNES 6631207

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital das Clínicas da UFG

Rua 235 QD. 68 Lote Área, Nº 285, s/nº - Setor Leste Universitário, Goiânia - GO, 74605-050 · CNES 2338424

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital das Clínicas da UFMG

Av. Prof. Alfredo Balena, 110 - Santa Efigênia, Belo Horizonte - MG, 30130-100 · CNES 2280167

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

NUPAD / Faculdade de Medicina UFMG

Av. Prof. Alfredo Balena, 189 - 5 andar - Centro, Belo Horizonte - MG, 30130-100 · CNES 2183226

Serviço de Referência

Rota
Erros Inatos do Metabolismo

Hospital Universitário João de Barros Barreto

R. dos Mundurucus, 4487 - Guamá, Belém - PA, 66073-000 · CNES 2337878

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas da Universidade Federal de Pernambuco

Av. Prof. Moraes Rego, 1235 - Cidade Universitária, Recife - PE, 50670-901 · CNES 2561492

Atenção Especializada

Rota
Erros Inatos do Metabolismo

Instituto de Medicina Integral Prof. Fernando Figueira (IMIP)

R. dos Coelhos, 300 - Boa Vista, Recife - PE, 50070-902 · CNES 0000647

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas da UFPR

R. Gen. Carneiro, 181 - Alto da Glória, Curitiba - PR, 80060-900 · CNES 2364980

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário Pedro Ernesto (HUPE-UERJ)

Blvd. 28 de Setembro, 77 - Vila Isabel, Rio de Janeiro - RJ, 20551-030 · CNES 2280221

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira (IFF/Fiocruz)

Av. Rui Barbosa, 716 - Flamengo, Rio de Janeiro - RJ, 22250-020 · CNES 2269988

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário Onofre Lopes (HUOL)

Av. Nilo Peçanha, 620 - Petrópolis, Natal - RN, 59012-300 · CNES 2408570

Atenção Especializada

Rota
Erros Inatos do Metabolismo

Hospital São Lucas da PUCRS

Av. Ipiranga, 6690 - Jardim Botânico, Porto Alegre - RS, 90610-000 · CNES 2232928

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital de Clínicas de Porto Alegre (HCPA)

Rua Ramiro Barcelos, 2350 Bloco A - Av. Protásio Alves, 211 - Bloco B e C - Santa Cecília, Porto Alegre - RS, 90035-903 · CNES 2237601

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário da UFSC (HU-UFSC)

R. Profa. Maria Flora Pausewang - Trindade, Florianópolis - SC, 88036-800 · CNES 2560356

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital das Clínicas da FMUSP

R. Dr. Ovídio Pires de Campos, 225 - Cerqueira César, São Paulo - SP, 05403-010 · CNES 2077485

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas da UNICAMP

R. Vital Brasil, 251 - Cidade Universitária, Campinas - SP, 13083-888 · CNES 2748223

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas de Ribeirão Preto (HCRP-USP)

R. Ten. Catão Roxo, 3900 - Vila Monte Alegre, Ribeirão Preto - SP, 14015-010 · CNES 2082187

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Instituto da Criança e do Adolescente (ICr-HCFMUSP)

Av. Dr. Enéas Carvalho de Aguiar, 647 - Cerqueira César, São Paulo - SP, 05403-000 · CNES 2081695

Serviço de Referência

Rota
Erros Inatos do Metabolismo

UNIFESP / Hospital São Paulo

R. Napoleão de Barros, 715 - Vila Clementino, São Paulo - SP, 04024-002 · CNES 2688689

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo
Sobre os centros SUS: Estes centros são habilitados pelo Ministério da Saúde como Serviços de Referência em Doenças Raras ou Serviços de Atenção Especializada. O atendimento é pelo SUS, com encaminhamento da rede de atenção básica.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Pesquisa e ensaios clínicos

Nenhum ensaio clínico registrado para esta condição.

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
0 papers (10 anos)
#1

The influence of menstrual cycle on metabolic control and diet in patients with phenylketonuria.

Orphanet journal of rare diseases2025 Jul 13

Based on experiences from everyday clinical practice and indications from the literature, the menstrual cycle might impact on metabolic stability in patients with urea cycle disorders and organic acidurias. However, this connection has not yet been systematically investigated.Phenylketonuria (PKU) as the most prevalent inborn error of metabolism with its easily determinable biomarker is a suitable model disease to shed light on this question. In ten patients with classic PKU on a low protein diet and on an amino acid mixture, phenylalanine (Phe) was measured from dried blood spots twice a week for 6 months. During this time, the patients documented their menstrual cycle and filled in nutrition protocols since it is known that the menstrual cycle also influences nutritional behavior. Based on this cohort, we found a significant correlation between the phases of the menstrual cycle and Phe concentration, with the lowest concentrations in the early luteal phase and the highest in the early follicular phase, during menstrual bleeding. This effect did not appear to be due to a change in eating behavior, as both protein and calorie intake were not significantly different in relation to the menstrual cycle. Since the increase in Phe began before menstrual bleeding, it does also not appear to be a pure effect of catabolism due to bleeding. Further studies will be required to identify the cause of this effect and to develop possible therapeutic strategies.

#2

Qatar's National Expanded Metabolic Newborn Screening Program: Incidence and Outcomes.

International journal of neonatal screening2025 Jun 30

Newborn screening is an essential public health strategy that aims to detect a range of conditions, including inborn errors of metabolism, in neonates shortly after birth. The timely identification is crucial due to the asymptomatic nature of many conditions at birth, but which can lead to significant health complications if left untreated. Through this study, we aimed to investigate the incidence of IEMs screened by the Qatar National Newborn Screening Program. We retrospectively analyzed a total of 351,223 newborns screened from 2010 to 2023. The incidence for the studied IEMs was calculated and correlated with demographics, consanguinity, and family history. In addition, the diagnostic yield of different tests utilized was assessed. Our study revealed a total of 318 positive cases with IEMs, and a significantly high incidence of 1:1105 for IEMs in Qatar. Classical Homocystinuria was the most frequently detected condition, with a cumulative incidence of 1:6754 live births, linked to the founder variant p. Arg336Cys in the CBS gene. Aminoacidopathies were the most prevalent category, followed by fatty acid oxidation disorders, organic acidurias, biotinidase deficiency, and urea cycle disorders. Genetic testing showed a high diagnostic yield of 90%. Of the 60 cases that underwent targeted variant testing, 98% were confirmed, while 90% of the 59 cases tested by single gene testing were confirmed. Our study provides the incidence rates of IEMs in Qatar and novel insights that could facilitate setting up/developing IEM incidence-reducing strategies and improving outcomes for affected newborns and their families.

#3

Genetic, neuroimaging, and clinical characteristics of a cohort of individuals with L-2-hydroxyglutaric aciduria from Türkiye.

Journal of pediatric endocrinology & metabolism : JPEM2025 Sep 25

L-2-hydroxyglutaric aciduria (L2HGA) is a hereditary metabolic disorder characterized by the accumulation of L-2-hydroxyglutaric acid in body fluids, particularly in cerebrospinal fluid, which disrupts neuron function in the central nervous system and triggers oxidative stress. It can cause seizures, developmental disorders, and behavioral abnormalities. The study retrospectively evaluated the demographic information, initial symptoms, clinical characteristics, cranial magnetic resonance imaging (MRI) findings, and post-treatment biochemical changes of 10 cases diagnosed with L2HGA. The study included five paediatric and five adult cases with a molecular diagnosis of L2HGA. The mean age at diagnosis was 10.1 years. Convulsion was identified as the primary presenting symptom in 70 % of cases. We identified intellectual disability in 80 % of our cases. In addition to the classic cranial MRI findings of subcortical white matter involvement, basal ganglia involvement was detected in 60 % of cases. We found that 2-hydroxyglutaric acid levels in urine organic acid analysis were significantly decreased riboflavin and carnitine post-treatment, with a mean decrease of 133.89 ± 101.43 mmol/mol creatinine (p=0.017). The most common missense variant identified in the L2HGDH gene was c.905C>T (p.Pro302Leu), occurring at a frequency of 50 % (5/10). The cases did not report significant improvement in their symptoms with treatment. L2HGA is a rare metabolic disorder that is more common in communities where consanguineous marriages are prevalent. Early diagnosis enables early treatment and protection of the brain from oxidative stress. As more cases are reported publicly, studies on genotype-phenotype relationships will yield more significant findings.

#4

Are protein substitutes available in Italy for infants with inherited metabolic diseases all the same?

Frontiers in nutrition2025

Inherited metabolic diseases (IMDs) represent a major clinical challenge, especially during the neonatal and infant periods. They require tailored and long-term nutritional management to ensure proper growth and development. Protein substitutes are essential in the dietary treatment of IMDs, particularly aminoacidopathies, organic acidemias, and urea cycle disorders. In Italy, a variety of PSs is available for infants with IMDs requiring a controlled protein and/or amino acid intake; however, differences in their nutritional composition may impact clinical outcomes. This study aims to examine and compare the nutritional composition of infant PSs (IPSs) available on the Italian market, focusing on macronutrients, micronutrients, and functional components. The analysis targets products used in the dietary management of aminoacidopathies, organic acidemias, and urea cycle disorders during the first year of life. We compared the nutritional composition of products intended for healthy infants, considering the Commission Delegated Regulation (EU) 2016/127 and Commission Delegated Regulation (EU) 2016/128. Phenylketonuria is excluded from this analysis, as it has been recently addressed in another paper. For each condition, there are only two products available, except for isovaleric aciduria and urea cycle disorders, which have only one product. The results indicate higher energy, linoleic, and alpha-linolenic acid content (+9%, +55%, and +290% compared to the maximum reference value), and lower levels of lactose, vitamin D, choline, selenium, and iodine (-92%, -34%, -37%, -12%, and -39% compared to the minimum reference value) for several IPSs. The analysis revealed the presence of docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA) in all IPSs, while half of them contain arachidonic acid (ARA). This study represents the first comprehensive comparison of the nutritional profiles of IPSs for IMDs on the Italian market. The results identify potential areas for optimization, aiming to provide adequate levels of micronutrients, essential fatty acids, and functional ingredients, such as biotics, to support gut health, immune function, and neurodevelopment.

#5

White matter abnormalities in amino acid disorders and organic acidurias.

Handbook of clinical neurology2024

Inborn errors of metabolism (IEMs) are traditionally the domain of pediatricians and internists for metabolic diseases. In general, neurologists only become involved when these disorders are complicated by neurologic symptoms such as seizures, developmental delay, or motor problems. However, in recent years and mainly due to the successes of next-generation sequencing, the number of IEMs primarily presenting with neurologic symptoms and not detected by classic biochemical testing has grown significantly. This in particular relates to disorders in the biosynthesis of amino acids. Therefore, I will start by discussing defects in the synthesis pathways of the amino acids serine, glutamine, proline, and asparagine. In these disorders, the amino acid can be low in body fluids with biochemical testing, but more frequently are completely normal and although are in different metabolic pathways, they share many clinical features such as hypomyelination and white matter abnormalities. Next, I will discuss classic amino acid disorders and organic acid disorders due to defects in breakdown pathways characterized by elevations of key metabolites in body fluids and associated with neurologic abnormalities and white matter changes on MRI. Individuals with clinical manifestations of isovaleric acidemia (IVA) have either classic IVA identified on newborn screening or classic IVA with a later diagnosis due to a missed diagnosis or later onset of clinical manifestations. Classic IVA is characterized by acute metabolic decompensations (vomiting, poor feeding, lethargy, hypotonia, seizures, and a distinct odor of sweaty feet). Acute metabolic decompensations are typically triggered by fasting, (febrile) illness (especially gastroenteritis), or increased protein intake. Clinical deterioration often occurs within hours to days after birth. Additional manifestations of classic IVA include developmental delay, intellectual disability and/or impaired cognition, epilepsy, and movement disorder (tremor, dysmetria, extrapyramidal movements). Early treatment in those identified by newborn screening can significantly reduce morbidity and mortality in individuals with classic IVA. The diagnosis of classic IVA is established in a proband by identification of C5-carnitine metabolites by tandem mass spectrometry and isovalerylglycine (IVG) and 3-hydroxyisovaleric acid (3-HIVA) on analysis of urinary organic acids by gas chromatography-mass spectrometry, or identification of biallelic pathogenic variants in IVD by molecular genetic testing. Targeted therapy: Low-leucine/protein-reduced diet and the supplementation of a leucine-free formula in infants or leucine-free amino acid mixture in older children; carnitine and/or glycine supplementation. Supportive care: Routine daily treatment includes education of affected individuals and caregivers about the natural history, maintenance and emergency treatment, prognosis, and risks of acute encephalopathic crises; emergency treatment letter and MedicAlert®; management of movement disorder per neurologist; physical therapy and aggressive rehabilitation therapy for gross motor delay; notify metabolic center prior to planned surgeries; consult metabolic disease specialist with any emergency surgery/procedure. Emergency outpatient treatment includes carbohydrate supplementation orally or via tube feeding, transient reduction of natural protein intake, elevation of carnitine supplementation, and glycine; antipyretics for fever; antiemetics for vomiting. Acute inpatient treatment includes stopping protein intake, intravenous glucose, and hydration with normal saline; adjusting treatments for new or evolving neurologic manifestations; consider buffers as needed for life-threatening metabolic acidosis; nitrogen scavengers for hyperammonemia. Surveillance: Quantitative analysis of plasma amino acids at least every three months until age one year, every six months from age one to six years, and annually in those age six years and older; blood gases, albumin, calcium, phosphate, parathyroid hormone, complete blood count, and vitamin B12 at least annually in those on a protein-restricted diet; measurement of growth and head circumference at each visit throughout childhood; monitor weight throughout adulthood; monitor developmental milestones at each visit; neuropsychological testing and standardized quality-of-life assessments as needed; assessment of movement disorder at each visit. Agents/circumstances to avoid: Excess of dietary protein or protein malnutrition inducing catabolic state; prolonged fasting; catabolism during illness. Evaluation of relatives at risk: Biochemical or molecular genetic testing of all at-risk sibs of any age is warranted to allow for early diagnosis and treatment of classic IVA. Classic IVA is inherited in an autosomal recessive manner. If both parents are known to be heterozygous for an IVD pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Once the IVD pathogenic variants have been identified in an affected family member, carrier testing for at-risk relatives and prenatal and preimplantation genetic testing are possible.

Publicações recentes

Ver todas no PubMed

📚 EuropePMCmostrando 18

2025

Qatar's National Expanded Metabolic Newborn Screening Program: Incidence and Outcomes.

International journal of neonatal screening
2025

Genetic, neuroimaging, and clinical characteristics of a cohort of individuals with L-2-hydroxyglutaric aciduria from Türkiye.

Journal of pediatric endocrinology & metabolism : JPEM
2025

The influence of menstrual cycle on metabolic control and diet in patients with phenylketonuria.

Orphanet journal of rare diseases
2025

Are protein substitutes available in Italy for infants with inherited metabolic diseases all the same?

Frontiers in nutrition
2024

White matter abnormalities in amino acid disorders and organic acidurias.

Handbook of clinical neurology
2023

Cardiac Involvement in Classical Organic Acidurias: Clinical Profile and Outcome in a Pediatric Cohort.

Diagnostics (Basel, Switzerland)
2021

Combined Malonic and Methylmalonic Aciduria Due to ACSF3 Variants Results in Benign Clinical Course in Three Chinese Patients.

Frontiers in pediatrics
2022

Hyperammonemia in Inherited Metabolic Diseases.

Cellular and molecular neurobiology
2021

Long-term N-carbamylglutamate treatment of hyperammonemia in patients with classic organic acidemias.

Molecular genetics and metabolism reports
2020

3-Methylglutaric acid in energy metabolism.

Clinica chimica acta; international journal of clinical chemistry
2019

Neurological manifestations of organic acidurias.

Nature reviews. Neurology
2019

Muscle Weakness, Cardiomyopathy, and L-2-Hydroxyglutaric Aciduria Associated with a Novel Recessive SLC25A4 Mutation.

JIMD reports
2017

"Classical organic acidurias": diagnosis and pathogenesis.

Clinical and experimental medicine
2016

Carglumic acid enhances rapid ammonia detoxification in classical organic acidurias with a favourable risk-benefit profile: a retrospective observational study.

Orphanet journal of rare diseases
2016

Hyperprolinemia in Type 2 Glutaric Aciduria and MADD-Like Profiles.

JIMD reports
2016

Inherited metabolic disorders in Turkish patients with autism spectrum disorders.

Autism research : official journal of the International Society for Autism Research
2015

The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 2: the evolving clinical phenotype.

Journal of inherited metabolic disease
2015

Rare presentation of a treatable disorder: glutaric aciduria type 1.

The New Zealand medical journal

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Acidúria orgânica clássica.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Acidúria orgânica clássica

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ordenadas pelo número de sintomas em comum.

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. The influence of menstrual cycle on metabolic control and diet in patients with phenylketonuria.
    Orphanet journal of rare diseases· 2025· PMID 40653469mais citado
  2. Qatar's National Expanded Metabolic Newborn Screening Program: Incidence and Outcomes.
    International journal of neonatal screening· 2025· PMID 40700042mais citado
  3. Genetic, neuroimaging, and clinical characteristics of a cohort of individuals with L-2-hydroxyglutaric aciduria from Türkiye.
    Journal of pediatric endocrinology & metabolism : JPEM· 2025· PMID 40660807mais citado
  4. Are protein substitutes available in Italy for infants with inherited metabolic diseases all the same?
    Frontiers in nutrition· 2025· PMID 40491588mais citado
  5. White matter abnormalities in amino acid disorders and organic acidurias.
    Handbook of clinical neurology· 2024· PMID 39322378mais citado
  6. Natural waxes from plant and animal origin as dielectrics for low-voltage organic field effect transistors.
    J Mater Chem C Mater· 2025· PMID 40606595recente
  7. Stereoselective 1,3-Cyclotelomerization of Butadiene with Dienophiles under Nickel Catalysis.
    J Am Chem Soc· 2025· PMID 40399751recente
  8. The Chemistry and Bioactivity of Mefenamic Acid Derivatives: A Review of Recent Advances.
    Arch Pharm (Weinheim)· 2025· PMID 40376734recente
  9. In Crystallo Wolff Rearrangement of a Metalated Diazoester: Structural Confirmation of the Singlet Carbene Wolff-Intermediate.
    J Am Chem Soc· 2025· PMID 39932156recente
  10. Ni-catalysed acceptorless dehydrogenative aromatisation of cyclohexanones enabled by concerted catalysis specific to supported nanoparticles.
    Nat Commun· 2025· PMID 39920108recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:79163(Orphanet)
  2. MONDO:0019215(MONDO)
  3. GARD:18947(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q55788539(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Compêndio · Raras BR

Acidúria orgânica clássica

ORPHA:79163 · MONDO:0019215
🇧🇷 Brasil SUS
Triagem
MS/MS — acilcarnitinas + ácidos orgânicos
PNTN
Fase 2
Incidência BR
1:20.000
Geral
CID-11
Medicamentos
1 registrados
MedGen
UMLS
C5681291
Wikidata
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades